Eqis Capital Management Inc. increased its stake in Novartis AG (NYSE:NVS) by 7.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 19,586 shares of the company’s stock after purchasing an additional 1,281 shares during the quarter. Eqis Capital Management Inc.’s holdings in Novartis were worth $1,883,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of NVS. Truvestments Capital LLC purchased a new position in shares of Novartis during the 1st quarter valued at $25,000. Canton Hathaway LLC purchased a new position in shares of Novartis during the 1st quarter valued at $26,000. AlphaMark Advisors LLC purchased a new position in Novartis in the fourth quarter worth $30,000. Legacy Advisors LLC purchased a new position in Novartis in the first quarter worth $38,000. Finally, Laurel Wealth Advisors LLC purchased a new position in Novartis in the fourth quarter worth $35,000. 11.72% of the stock is currently owned by institutional investors.
Shares of NYSE:NVS traded up $0.90 during midday trading on Friday, hitting $81.88. 2,047,120 shares of the stock traded hands, compared to its average volume of 3,055,513. Novartis AG has a one year low of $63.60 and a one year high of $85.08. The company has a current ratio of 0.93, a quick ratio of 0.83 and a debt-to-equity ratio of 0.48. The company has a market cap of $187.06 billion, a price-to-earnings ratio of 16.09, a price-to-earnings-growth ratio of 1.95 and a beta of 0.66.
NVS has been the subject of several research reports. Liberum Capital upgraded shares of Novartis from a “hold” rating to a “buy” rating in a research report on Thursday, April 25th. Guggenheim upgraded shares of Novartis from a “neutral” rating to a “buy” rating and set a $79.16 target price for the company in a research report on Wednesday, April 24th. JPMorgan Chase & Co. reiterated a “sell” rating on shares of Novartis in a research report on Tuesday, January 29th. Zacks Investment Research lowered shares of Novartis from a “hold” rating to a “strong sell” rating in a research report on Thursday, April 11th. Finally, Morgan Stanley lowered shares of Novartis from an “equal weight” rating to an “underweight” rating and upped their target price for the stock from $82.50 to $82.52 in a research report on Wednesday, April 10th. Five equities research analysts have rated the stock with a sell rating, four have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $87.57.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Further Reading: What is a stock buyback?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.